Ovarian Cancer Clinical Trial Breakthroughs and Impact on Management

被引：12

作者：

Previs, Rebecca Ann ^{[1
]}

Secord, Angeles Alvarez ^{[1
]}

机构：

[1] Duke Univ, Duke Canc Inst, Dept Obstet & Gynecol, Div Gynecol Oncol,Med Ctr, Box 3079, Durham, NC 27710 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2019年 / 46卷 / 01期

关键词：

Ovarian cancer; Clinical trials; Cytoreduction; PARP inhibitor; Bevacizumab; Immunotherapy; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; PRIMARY PERITONEAL CANCER; PACLITAXEL PLUS CARBOPLATIN; PHASE-III TRIAL; OPEN-LABEL; DOUBLE-BLIND; NEOADJUVANT CHEMOTHERAPY; FALLOPIAN-TUBE; 1ST-LINE CHEMOTHERAPY;

D O I：

10.1016/j.ogc.2018.09.005

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance therapy. Maintenance therapy has been shown to enhance progression-free survival. Recent surgical trials have evaluated the role of neoadjuvant chemotherapy versus primary debulking at the time of diagnosis in advanced stage ovarian cancer. The role of lymph node dissection and secondary cytoreductive surgeries have also been evaluated. This article reviews contemporary trials of maintenance therapy and novel drug development.

引用

页码：67 / +

页数：23

共 50 条

[1] MANAGEMENT OF OVARIAN-CANCER - COSA CLINICAL-TRIAL
TATTERSAL, M
SOLOMON, HJ
MEDICAL JOURNAL OF AUSTRALIA, 1979, 1 (12) : 553 - &
[2] Impact of PET/CT with FDG on the clinical management of patients with ovarian cancer
Volterrani, D.
Filidei, E.
Cosio, S.
Grosso, M.
Manca, G.
Paglianiti, I.
Chiacchio, S.
Guidoccio, F.
Boni, G.
Gadducci, A.
Mariani, G.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S297 - S297
[3] Breakthroughs in lung cancer management
Montuenga, L. M.
Zulueta, J. J.
ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2020, 43 (02) : 131 - 139
[4] Management of ovarian cancer: Clinical trials
Markman, Maurie
Intraperitoneal Cancer Therapy, 2007, : 11 - 29
[5] Principles of clinical management of ovarian cancer
Gorodnova, Tatiana V.
Sokolenko, Anna P.
Kuligina, Ekatherina
Berlev, Igor V.
Imyanitov, Evgeny N.
CHINESE CLINICAL ONCOLOGY, 2018, 7 (06)
[6] THE IMPACT OF AGE ON THE MANAGEMENT OF PATIENTS WITH OVARIAN CANCER
Laudani, M. E.
Potenza, E.
Fuso, L.
Moro, F.
Macchi, C.
Ribotta, M.
Zola, P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A486 - A486
[7] THE IMPACT OF GUIDELINES IN THE OVARIAN CANCER MANAGEMENT. A POPULATION-BASED CLINICAL AUDIT
Sobrero, S.
Pagano, E.
Mitidieri, M.
Macchi, C.
Mistrangelo, M.
Bertetto, O.
Patriarca, S.
Zanetti, R.
Ferrero, A.
Ciccone, G.
Zola, P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 564 - 564
[8] Clinical Impact of RANK Signalling in Ovarian Cancer
Wieser, Verena
Sprung, Susanne
Tsibulak, Irina
Haybaeck, Johannes
Hackl, Hubert
Fiegl, Heidelinde
Marth, Christian
Zeimet, Alain Gustave
CANCERS, 2019, 11 (06)
[9] Immunonutrition in ovarian cancer: clinical and immunological impact?
Ferrero, Annamaria
Vassallo, Daniela
Geuna, Massimo
Fuso, Luca
Villa, Michela
Badellino, Enrico
Barboni, Martina
Coata, Paola
Santoro, Nathalie
Delgado Bolton, Roberto C.
Biglia, Nicoletta
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (06)
[10] Clinical management of ovarian cancer and the role of the pathologist
不详
PATHOLOGY RESEARCH AND PRACTICE, 2005, 201 (03) : 215 - 216

← 1 2 3 4 5 →